A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Ascending Intravenous Doses of Glofitamab, Administered after Ocrelizumab Pretreatment, in Patients with Multiple Sclerosis
This early-stage study is researching a new medicine called glofitamab for people with multiple sclerosis (MS). Before receiving glofitamab, participants will take another existing MS medicine called ocrelizumab. The main goals are to check the safety of glofitamab and how well people tolerate it. Researchers will also learn how the body uses and processes the drug (pharmacokinetics) and how it affects the disease on a cellular level (pharmacodynamics). This will help them understand if glofitamab could be a helpful future treatment option for MS. This type of study is an important first step in understanding new medicines.
At a glance
What is this study about?
This research study is about a new investigational medicine called glofitamab for people living with multiple sclerosis (MS). MS is a condition that affects your brain and spinal cord, causing a range of symptoms. Finding new treatments is very important to help manage the condition and improve people's lives.
The study is in its very early stages, sometimes called 'Phase I'. This means researchers are focused on understanding the new medicine's basic properties. They want to find out if it's safe to use, how much of it the body can handle without causing too many side effects, and how it behaves inside the body. This includes looking at how quickly the body absorbs, processes, and removes the drug, and what effects it has on the body at a cellular level.
Before taking glofitamab, participants in this study will first receive a different, existing MS medicine called ocrelizumab. This step is part of how the researchers are carefully testing the new medicine. The information gathered in this study will help determine if glofitamab has the potential to become a future treatment option for MS.
Key takeaways
- This is an early-stage study for a new MS medicine called glofitamab.
- It aims to check the safety and how well people tolerate the new treatment.
- Participants will first receive an existing MS medicine, ocrelizumab.
- The study helps researchers understand how the new medicine works in the body.
- You must be 18 years or older and have MS to be considered.
Who may be eligible?
To join this study, you need to be an adult, 18 years old or older. The study welcomes both men and women who have been diagnosed with multiple sclerosis (MS).
While the raw information doesn't give many details, generally, studies like this look for people who meet specific health criteria related to their MS and overall health. For example, they often need to have a certain type of MS, have not taken particular other medications recently, and have no other serious health conditions that could make taking part unsafe.
It's important to discuss your full medical history with the study team to see if you meet all the requirements. They will ask you detailed questions to make sure the study is a good fit for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with Multiple Sclerosis (MS)?
- Are you able to commit to regular hospital visits and follow-up appointments?
- Are you comfortable with receiving medication through an IV (drip into your arm)?
- Have you discussed your overall health and any other medical conditions with your doctor?
What does participation involve?
If you decide to take part, you would receive the new medicine, glofitamab, which will be given directly into your vein (intravenous doses) after you've already had a dose of ocrelizumab. You'll have regular visits to the clinic so the study team can monitor your health closely. During these visits, there will be various assessments. These might include blood tests, physical examinations, and possibly scans or other tests to see how the new medicine is affecting your body and your MS.
The study will involve several visits over a period of time, and you'll have follow-up appointments even after you stop taking the study medication. The total length of your participation will be explained in detail by the study team. They will also tell you about any specific preparation needed for visits and how the medication will be given.
Potential risks and benefits
Locations (2)
- —UnverifiedCroatia
- —UnverifiedCzechia
Common questions
What is the new medicine called?
The new medicine being tested is called glofitamab.
What is the purpose of this study?
The study aims to check the safety, how well people tolerate it, and how the new medicine works in the body for people with MS.
Do I need to be taking another MS medication to join?
Yes, participants in this study will receive ocrelizumab before receiving the new medicine, glofitamab.
How old do I need to be to take part?
You need to be at least 18 years old to be considered for this study.
Will I definitely get better if I join?
No, there's no guarantee that participating in the study will improve your MS. The main goal is to understand the new medicine's safety and effects.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.